Comparing Ciprofol and Propofol for Sedation in Hypotensive ICU Patients: a Single Center Prospective Cohort Study

Sponsor
Nanfang Hospital, Southern Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05971121
Collaborator
(none)
456
1
24
19

Study Details

Study Description

Brief Summary

This study was a single-center, prospective, 2-year observational cohort study. The study subjects were ICU patients requiring vasopressor drugs and requiring sedation. According to the use of ciprofol or propofol in the treatment plan (determined by the doctor in charge according to the condition of the subjects), they were divided into groups: ciprofol group and propofol group. A total of 456 subjects were planned to be enrolled, including 304 subjects in the cyclopofol group and 152 subjects in the propofol group. The data of this study were obtained by extracting the routine clinical diagnosis and treatment records of the enrolled subjects.

Condition or Disease Intervention/Treatment Phase

Study Design

Study Type:
Observational
Anticipated Enrollment :
456 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Comparing Ciprofol and Propofol for Sedation in Hypotensive ICU Patients: a Single Center Prospective Cohort Study
Actual Study Start Date :
Oct 1, 2022
Anticipated Primary Completion Date :
Oct 1, 2024
Anticipated Study Completion Date :
Oct 1, 2024

Arms and Interventions

Arm Intervention/Treatment
ciprofol group

Hypotensive ICU patient sedated with ciprofol

Drug: ciprofol
Ciprofol were used for sedation in ICU hypotensive patients

propofol group

Hypotensive ICU patient sedated with propofol

Outcome Measures

Primary Outcome Measures

  1. The proportion of patients meeting the RASS sedation [within 24 hours]

    Professionally trained researchers perform RASS scores on patients at specific time points

Secondary Outcome Measures

  1. Dosage of propofol or ciprofol during sedation (total dose/time of use) [up to 24 hours]

    Responsible researchers consult the patient's medical record after completing treatment to obtain the dosage and duration of medication

  2. Dosage of norepinephrine during sedation (total dose/time of use) [up to 24 hours]

    Responsible researchers consult the patient's medical record after completing treatment to obtain the dosage and duration of medication

  3. Duration of mechanical ventilation [From endotracheal intubation to withdrawal from mechanical ventilation,up to 28 days]

    Responsible researchers obtain information by viewing electronic medical records

  4. Incidence of adverse events [up to 3 days]

    The occurrence of adverse events during the hospital period will be recorded in the medical record by the clinician or nurse, and the researcher will obtain the occurrence of adverse events (event type, time, treatment, results, etc.) through the medical record

  5. length of ICU stay [up to 28 days]

    Researchers obtain it through the hospital electronic system

  6. The mortality rate [up to 28 days]

    Researchers obtain it through the hospital electronic system.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥ 18;

  • It needs to be treated with vasopressors to maintain mean arterial pressure ≥65 mmHg;

  • Sedative medication required for comfort, safety, and to facilitate life support measures;

  • Obtain the informed consent of the human subjects or their legal representatives.

Exclusion Criteria:
  • Pregnant patient;

  • Patients with proven acute severe intracranial or spinal neurological disease due to vascular, intracranial dilatation, or injury;

  • History of allergy to cyclopofol, propofol, eggs, or soy products;

  • History of long-term use of benzodiazepines or opioids;

  • Sedative drugs other than propofol or cyclopofol were used at enrollment, or propofol and cyclopofol were used alternately within 24 hours;

  • The researchers judged that they are not suitable to participate in this study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Southern medical university Nanfang hospital Guangzhou China 510515

Sponsors and Collaborators

  • Nanfang Hospital, Southern Medical University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Nanfang Hospital, Southern Medical University
ClinicalTrials.gov Identifier:
NCT05971121
Other Study ID Numbers:
  • NFEC-2022-525
First Posted:
Aug 2, 2023
Last Update Posted:
Aug 2, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 2, 2023